FDA Panel Backs Previously Rejected Obesity Pill
A panel of advisers to the Food and Drug Administration overwhelmingly backed approval for a highly anticipated anti-obesity pill from Vivus Inc., a drug which the FDA previously rejected due to safety concerns.